Sanofi with a $9.1B Acquisition of Blueprint & Cancer Conference Shows Successes for Diagnostics, Therapy, and Treatments
- Jonathan Poyer
- Jun 4
- 2 min read
Sanofi has been busy on the acquisition front acquiring Vigil Neuroscience for $470M and Blueprint Medicines for $9.1B over the past month:
Sanofi acquired Blueprint Medicines for $9.1B or $129/share
Sanofi acquired Vigil Neuroscience for $470M or $8/share
Blueprint has one drug, which is approved in the US, Europe and elsewhere to treat gastrointestinal stromal tumors as well as systemic mastocytosis. Blueprint reported 2024 sales of $479M for its flagship drug, Avaykit.
Another highlight is that the largest cancer conference, the American Society of Clinical Oncology (ASCO) wrapped up this week and there has been a ton of news flow.
Several updates from diagnostic companies like PSNL, NTRA, and GH showcasing the value of minimal residual disease testing in cancer. This is essentially a blood test to characterize and track cancer upon diagnosis and post-treatment. By testing, doctors are finding they can diagnose recurrence earlier and determine best courses of treatment with more information.
Bispecifics abound! Numerous updates from companies like BNTX, JAZZ, GMAB, and JNJ highlighted that two is better than one in several indications. A bispecific antibody, unlike monoclonal antibodies, targets more than one protein. For example, several companies are working on assets currently targeting VEGF-A and PD-L(1) at the same time vs. individually (BNTX, PFE, SMMT, among others). Of note, a collaboration between BMY and BNTX was announced for this asset today.
Targeted therapies continue to show promise in mutated cancers. VSTM, MRK, and LLY each presented data pertaining to their KRAS programs, targeted to either G12C or G12D mutation status. As our tumor characterization improves, tailored therapies are likely to continue to evolve.
Maybe uncertainty is starting to wane, and we can see the sector finally have a breakout!
Comments